328P - Survival outcomes in patients with stage IVB, persistent or recurrent adenocarcinoma of the cervix treated with combination chemotherapy

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Cervical Cancer
Presenter Tisana Anantawat
Citation Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585
Authors T. Anantawat, K. Rittiluechai
  • Gynecologic Oncology, Phramongkutklao Hospital, 10400 - Bangkok/TH



Although the falling incidences of squamous cell carcinoma, the proportion of adenocarcinoma of uterine cervix increased with accounting for 15 to 24% of all cervical cancer cases. Controversial data about prognosis and survival of squamous cell carcinoma and adenocarcinoma of uterine cervix. The standard treatment of stage IVB, persistent or recurrent cervical carcinoma have not been established. A few prior studies had a majority of patient with adenocarcinoma. Various of chemotherapy regimens were used in these studies, and conclusions were still unclear. The main objective of this study was to evaluate an overall survival outcome of patients with stage IVB, persistent, or recurrent adenocarcinoma of uterine cervix in Phramongkutklao Hospital. A progression free survival, response rate, and prognostic factors were also calculated.


A retrospective study was conducted. All patients with stage IVB, persistent, or recurrent disease who were treated between July 1993 and June 2013 were included. Patients’ baseline characteristics were collected. Overall survival and progression free survival were calculated by Kaplan-Meier survival analysis.


Forty patients were enrolled with a mean age of 51.4 years old. The chemotherapy regimens used in this study were cisplatin plus ifosfamide (CIf), cisplatin plus irinotecan (CIr), platinum-based chemotherapy plus paclitaxel (PP), and another 4 regimens. The median overall survivals of all 40 patients were 7.8 months. The median overall survivals were 6.7, 11.2, 5.5, and 9.3 months for CIf, CIr, PP and other regimens group, respectively. Most adverse effects were manageable. The most common adverse effect was hematologic toxicity. Many prognostic factors were evaluated in this study such as age > 60 years, hemoglobin level < 12 g/dl, relapse inside previous irradiation field, and time to relapse less than 6 months. No demonstrable prognostic factor was found in univariate analysis.


Cisplatin plus irinotecan achieved a highest response rate and overall survival time without a significant difference when compare with other regimens. Further study with a larger population and prospective method is needed for the better conclusion.

Clinical trial indentification

R136q/58_Exp November 10th, 2015

Legal entity responsible for the study

Phramongkutklao Hospital


Phramongkutklao Hospital


All authors have declared no conflicts of interest.